Versatile Modular Viral Platform (MVP) for In Vivo Reprogramming for Oncology & Beyond

Time: 4:30 pm
day: Day One

Details:

• Building on 20+ years of technology and clinical advances with in vivo administration of retroviral vectors
• Success factors for in vivo reprogramming
• Leveraging scalable manufacturing to meet the patient need